CEO David Hipkiss made the prediction at CPhI 2010 in Paris, citing the application of Prosonix’ Umax technology to a combination therapy being developed by Italian drugmaker Cheisi, as the most recent example of this trend.
He went on to explain that unlike combination therapies that have suboptimal co-association rates between their constituent long-acting beta agonist (LABA) and steroid ingredients as a result of traditional particle production methods, Umax has allowed Chiesi to make a product with a co-association rate of one to 50, potentially boosting its therapeutic efficacy.
Hipkiss also predicted the expiry of patents for some 75 per cent of branded respiratory drugs over the next few yeas will drive demand for particle technologies from both Big Pharma’s keen to reformulate and generics companies which, although keen to enter the market, may lack the technical expertise required to do so.
*all puns intended